Concurrent gliomas in patients with multiple sclerosis

Study population

In this multicenter, retrospective analysis, we collected 30 brain tumor tissue samples diagnosed between 01 January 2001 and 31 December 2017 and clinical and radiographical data of patients with reported multiple sclerosis from the Departments of Neuropathology, Neurology and Neurosurgery, University of Heidelberg; the Departments of Neurology and Neurosurgery, University Medical Center Mannheim of Heidelberg University; Dr Senckenberg Institute of Neurooncology, University of Frankfurt, and the Department of Neurology, University of Tübingen (all located in Germany). Four cases were excluded due to tumor histology other than glioma or insufficient proof of multiple sclerosis diagnosis according to the revised McDonald criteria ¹⁵ resulting in a study population of 26 patients in the experimental cohort. Control cases with isocitrate dehydrogenase (IDH)-mutant 1p19q-intact astrocytoma WHO grade II or IDH-wildtype glioblastoma WHO grade IV were collected from the Departments of Neuropathology, Neurology, and Neurosurgery, University of Heidelberg, and matched for tumor histology and the known prognostic markers IDH- and O6-methylguanine-DNA methyltransferase (MGMT)-status, age at diagnosis, and Karnofsky-Index. Tissue sample collection and data collection and use were performed following local ethics regulations and approved by the local ethics committee (ethics votes 005/2003, 2013-832R-MA, 2018-614N-MA).

Clinical assessments

Progression-free survival (PFS), defined as the time from brain tumor surgery to the date of tumor progression, was assessed based on follow-up imaging performed under the response assessment in neuro-oncology (RANO) criteria ^16,17. The overall survival (OS) was defined as the time from surgery to the date of decease. Multiple sclerosis disease activity was assessed based on clinical attacks and MRI follow-up according to the revised McDonald criteria ¹⁵.

Methylation analysis

Bioinformatic analysis of Illumina 450k methylation array data was performed with customized scripts adapted from the R (www.r-project.org) based library “ChAMP” (version: 2.10.116) as described previously ¹⁸. At the Genomics and Proteomics Core Facility of the German Cancer Research Center (DKFZ) in Heidelberg, Germany, the Infinium HumanMethylation450 BeadChip and kits (Illumina, San Diego, CA, USA) were used according to manufacturer’s instructions to obtain the DNA methylation status at >450,000 sites in paraffin-embedded tissue derived from glioma patients with MS and matched controls. Raw data was loaded using the load() function in “ChAMP”. For multi-hit sites, SNPs, and XY chromosome related CpGs data was filtered; next, data was normalized with a BMIQ based method and analyzed for batch effects with a singular value decomposition (SVD) algorithm. There was no significant batch to be corrected. Respective functions were used to assess differentially methylated regions (DMR). Principle component analysis was used for dimensionality reduction. Circos plots showing DMR distribution were constructed with the package “OmicCircos” (version: 1.26.0).

Statistical analyses

Logistic regression analyses to calculate odds ratios (ORs) with 95% confidence intervals (CIs) were performed to compare clinical characteristics in the experimental cohort and control cohort. Distribution of survival times was estimated by the Kaplan–Meier method and compared between groups with the log-rank test. A p-value of less than 0.05 was considered significant.

Data availability

Source code can be made available on reasonable request.

Clinical characteristics of patients with multiple sclerosis and concurrent glioma

A multicenter, retrospective cohort of 26 patients with both MS and diffuse glioma, meeting the predefined inclusion criteria was assembled from four centers (Figure 1, Supplementary Table 1). A survey of 2809 brain tumor patients (C71 ICD-10-GM), diagnosed between 01 January 2007 and 31 December 2015, revealed no evidence of increased MS prevalence compared to published cohorts with or without autoimmune diseases (Anssar et al., 2020) (Supplementary Table 2). All gliomas had an astrocytic morphology, with IDH-mutant astrocytomas WHO grade II being the most frequent brain tumors in MS patients (46%), followed by IDH-wildtype glioblastomas WHO grade IV (31%). Median age at tumor diagnosis was 32.5 years for IDH-mutant astrocytomas and 59 years for glioblastomas, both within the age range expected for these tumor types ¹⁹ (Figure 2 A, Supplementary Table 3, 4). The mean age at MS diagnosis was 31 years and 40 years, respectively (Figure 2 B, Supplementary Table 5). The MS symptom course was relapsing-remitting in 19/26 (73%) cases and secondary progressive in 4/26 (15%). All patients had radiologically proven cerebral inflammatory lesions, 6/26 (23%) had spinal lesions, and 7/26 (27%) had optic neuritis. 15/26 (58%) patients received immunomodulatory treatment (Supplementary Table 1, Supplementary Figure 1 B).

• Download figure
• Open in new tab

Figure 1 Consort flow diagram of the multicenter study

• Download figure
• Open in new tab

Figure 2 Clinical and radiological characteristics of 19 patients with multiple sclerosis and concurrent glioma.

A+B Scatter dot plot of patients’ age at initial histologically proven diagnosis of glioma depending on the mutation status of isocitrate dehydrogenase-1 (IDH) in patients with concurrent multiple sclerosis (MS) or control patients without multiple sclerosis (ctl) (A), and patients’ age at initial multiple sclerosis diagnosis depending on tumoral IDH mutation status (B). Depicted are single and mean values with SEM.

C Chronology of multiple sclerosis and glioma diagnosis depending on tumor histology judged by IDH mutation status.

D Schematic representation of glioma location in patients with concurrent multiple sclerosis depending on tumoral IDH mutation status. Dots represent single patients.

E MRI with axial FLAIR and contrast-enhanced T1 images of a patient with multiple sclerosis and concurrent IDH-mutant astrocytoma WHO grade II (p02, upper row) and of a patient with multiple sclerosis and IDH-wildtype glioblastoma WHO grade IV (p08, lower row).

F Schematic representation of the spatial relation of multiple sclerosis lesions and IDH-mutant astrocytomas (red) or IDH-wildtype glioblastomas (blue) in patients with concurrent diseases.

While patients diagnosed with glioblastoma had a longstanding history of CNS inflammatory disease, patients diagnosed with IDH-mutant astrocytoma received MS diagnosis mostly at the same time or later. Subsequently, glioblastomas arose near existing inflammatory lesions, while IDH-mutant astrocytomas developed from radiologically normal-appearing white matter (NAWM) (Figure 2 D, E, F).

Concurrent multiple sclerosis diagnosis is associated with worse prognosis of IDH-mutant astrocytomas

Next, clinical data from glioma patients with concurrent MS were compared with data from control patients without MS and matched for tumor histology and the known prognostic markers IDH- and MGMT-status, age at diagnosis, and Karnofsky-Index (Supplementary Table 3, 4). The glioblastoma-related neurological symptoms and distinct radiological morphology led to prompt radiological tumor suspicion and subsequent histological diagnosis independent of MS comorbidity. In contrast, radiological findings in most MS patients with IDH-mutant astrocytoma WHO grade II occurred incidentally, with a median time of 21 months (0 – 68) between initial MRI suspicion and histological diagnosis (Figure 3 A, B). However, glioma size at the time of histological diagnosis was comparable between MS and control groups for both tumor types (Figure 3 C). For non-contrast enhancing lesions, results from non-invasive MRI spectroscopy could support tumor suspicion in one patient (Supplementary Figure 2). Glioma diagnosis was confirmed by biopsy in 14/26 (54%) cases, and 12/26 (46%) received partial or complete tumor resection. Remarkably, the proportion of patients receiving tumor biopsy was higher in MS patients than controls independent of tumor histology (29% vs. 14% for IDH-wildtype; 50% vs. 25% for IDH-mutant) (Figure 3 D). While all glioblastoma patients received standard tumor-specific treatment, except one non-MS patient receiving best supportive care, the majority of patients with IDH-mutant astrocytomas were primarily treated with a watchful waiting approach according to the current standard of care independent of MS diagnosis (Figure 3 E). As expected ²⁰, patients with IDH-wildtype glioblastomas showed a significantly shorter PFS compared to patients with IDH-mutant astrocytomas independent of concurrent MS. Of note, multiple sclerosis was associated with a worse prognosis in IDH-mutant tumors only (PFS 32 vs. 64 months, p=0.0206) (Figure 3 F, Supplementary Figure 1 D). The limited sample size did not allow to firmly establish the impact of immunomodulatory treatments on brain tumor progression (Supplementary Figure 1 E).

• Download figure
• Open in new tab

Figure 3 Clinical course of brain tumor disease in patients with glioma and concurrent multiple sclerosis

A Percentage of patients with or without glioma-caused neurological symptoms leading to initial tumor diagnosis in patients with concurrent multiple sclerosis (MS) or matched controls (ctl) depending on tumoral IDH mutation status.

B Time between radiological tumor suspicion and subsequent histological diagnosis.

C Tumor size as detected by MRI at the time of histological diagnosis in patients with concurrent multiple sclerosis or matched controls depending on tumoral IDH mutation status. Displayed are the products of the two largest perpendicular diameters (cm²) in axial FLAIR or contrast-enhanced T1 images for IDH-mutant astrocytomas WHO grade II and IDH-wildtype glioblastomas, respectively.

D Percentage of patients receiving tumor biopsy, partial, or complete resection.

E Type of adjuvant tumor therapy depending on concurrent multiple sclerosis diagnosis and IDH mutation status.

F Kaplan–Meier analysis of progression-free survival (PFS) after primary tumor treatment depending on IDH status and concurrent multiple sclerosis diagnosis

Glioma radiotherapy as a possible risk factor for multiple sclerosis disease activity

The majority of patients were treated with radiotherapy (RT) alone or in combination with chemotherapy at one time during the course of brain tumor disease (83% in the IDH-mutant and 71% in the IDH-wildtype cohort) (Figure 4 A, Supplementary Figure 1 C). While none of the IDH-mutant astrocytoma patients showed clinical or radiological signs of multiple sclerosis disease activity according to NEDA-3 criteria within the 12 months prior to starting RT, 5/12 patients (42%) with multiple sclerosis and IDH-mutant astrocytoma showed disease activity within 12 months after RT, with an average of 1.4 clinical relapses. Remarkably, 89% of clinical episodes occurred within the first six months after RT and were associated with new contrast-enhancing lesions within or adjacent to the radiation field (Figure 4, Supplementary Figure 1 F). In 3/5 patients, radiation-associated neuroinflammation occurred despite immunomodulatory treatment, and in 2/5 patients, multiple sclerosis was initially diagnosed within six months after RT. Interestingly, one patient with IDH-wildtype glioblastoma experienced long-term survival with no evidence of tumor recurrence for eight years following radiation-induced pseudo-progression. The radiographical increase in disease activity was accompanied by neurological deterioration, leading to the initial diagnosis of a chronic progressive multiple sclerosis course eight months after completion of radiotherapy (Figure 5).

• Download figure
• Open in new tab

Figure 4 Association between radiotherapy and multiple sclerosis disease activity

A Percentage of patients with or without radiotherapy (RT) treatment during the course of brain tumor disease depending on concurrent multiple sclerosis (MS) diagnosis and tumoral IDH mutation status.

B Percentage of patients with or without clinical or radiological multiple sclerosis disease activity in the 12 months preceding (left bar) and after RT (right bar).

C Scatter dot plot of the number of clinical episodes per patient for six multiple sclerosis patients in the 12 months preceding and after RT. Depicted are single and mean values with SEM.

D Time course of cumulative clinical multiple sclerosis episodes for five multiple sclerosis patients experiencing disease activity in the 12 months after RT.

E MRI with axial FLAIR images of two patients showing new demyelinating lesions (arrows) after RT within the 50% isodose line (p02 photon irradiation 60/2Gy; p47 proton irradiation 54/1.8Gy).

• Download figure
• Open in new tab

Figure 5 Long-term response after radiation-induced pseudoprogression

Representation of isodoses (Gy) and longitudinal MRIs with axial FLAIR images (left column) and contrast-enhanced axial T1 images (right column) of a patient (p08) with IDH-wildtype glioblastoma WHO grade IV. Transient contrast enhancement within the tumor area corresponding to radiation-induced pseudoprogression with a maximum of 8 months after completion of radiotherapy (60/2Gy) is associated with an increase in subcortical multiple sclerosis lesions (arrows) and the initial diagnosis of a chronic progressive multiple sclerosis course. Long term follow-up shows a moderate generalized brain atrophy (stars) without evidence of glioblastoma recurrence up to 8 years after initial tumor therapy.

Genome-wide methylation analysis of glioma samples identified DMRs associated with neuroinflammation

Genome-wide methylation patterns of glioma tissue from 12 multiple sclerosis patients and the matched control cohort without multiple sclerosis were compared to address the question if chronic neuroinflammation may predispose susceptibility to the exacerbation of focal disease activity on a molecular level in multiple sclerosis patients after radiotherapy (Supplementary Table 3, 4). While principal component analysis and unsupervised clustering revealed no distinct subgroup-defining methylation pattern depending on multiple sclerosis diagnosis, analysis of DMRs identified 117 DMRs in IDH-mutant astrocytomas and 103 DMRs in IDH-wildtype glioblastomas, with 11 common DMRs possibly associated with multiple sclerosis (Figure 6 A, Supplementary Figure 3). Interestingly, DMRs build a hotspot on the short arm of chromosome 6 (p21.32) within the human leukocyte antigen (HLA) region (Figure 6 B). The HLA system plays a critical role in immune regulation by presenting epitopes to leukocytes and thereby releasing antigen-specific immune responses ²¹. For multiple sclerosis, the HLA system has been shown to comprise major susceptibility loci (Gourraud et al., 2012), and the aberrant methylation patterns of specific HLA genes in NAWM of multiple sclerosis patients are thought to be relevant for multiple sclerosis etiology (Huynh et al., 2014). Moreover, most known multiple sclerosis risk genes belong to the immune system, and genetic regions related to innate immunity are thought to constitute glioma risk factors (Plantone et al., 2015). In line, additional DMRs are located on chromosome 5q31 within the interleukin (IL) region and include genes associated with myelinization and immune function (Supplementary Table 6). These data suggest that epigenetic changes in inflammatory genes in NAWM predispose to exacerbation of neuroinflammation by focal irradiation.

• Download figure
• Open in new tab

Figure 6 Genome-wide DNA methylation changes between gliomas of patients with concurrent multiple sclerosis and controls

A Unsupervised hierarchical clustering of methylation profiles from 850k methylation array data of 12 glioma tissue in multiple sclerosis (MS) patients and matched controls.

B Circos plot showing DMR between patients with and without multiple sclerosis separately for IDH^mut (inner two circles) and IDH^wt tumors (outer two circles) on each of the human chromosomes with a zoom in on chromosome 6. The inner cirle of the respective comparisons show the average methylation, the outer circle the area of the DMR.